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Abstract
Background: The global prevalence of chronic kidney disease (CKD) is increasing. In children, CKD exhibits unique
etiologies and can have serious impacts on children’s growth and development. Therefore, an aggressive approach
to preventing the progression of CKD and its complications is imperative. To improve the understanding and
management of Asian pediatric patients with CKD, we designed and launched KNOW-Ped CKD (KoreaN cohort
study for Outcome in patients With Pediatric Chronic Kidney Disease), a nationwide, prospective, and observational
cohort study of pediatric CKD with funding from the Korean government.
Methods/design: From seven major centers, 450 patients <20 years of age with CKD stages I to V are recruited for
the comprehensive assessment of clinical findings, structured follow-up, and bio-specimen collection. The primary
endpoints include CKD progression, defined as a decline of estimated glomerular filtration rate by 50 %, and a
requirement for renal replacement therapy or death. The secondary outcomes include the development of left
ventricular hypertrophy or hypertension, impairment of growth, neuropsychological status, behavioral status, kidney
growth, and quality of life.
Discussion: With this study, we expect to obtain more information on pediatric CKD, which can be translated to
better management for the patients.
Trial registration: NCT02165878 (ClinicalTrials.gov), submitted on June 11, 2014.
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Background
Globally and locally, the prevalence of chronic kidney
disease (CKD) is increasing along with prolonged life-
spans and over-nutrition in many areas of the world [1].
The development of genomics and health technology
has enabled genetic diagnoses of rare and common dis-
eases and interventions for improving the outcome of
previously untreatable diseases, such as congenital neph-
rotic syndrome of the Finnish type. Additionally, the life
expectancy of cancer survivors and extremely low birth
weight preterm infants has continued to improve, not
infrequently along with secondary CKD. Therefore, the
numbers of children with CKD of both primary and sec-
ondary causes have increased, and the proportion of
CKD in renal patients is increasing.
To treat failed kidneys, nephrologists use powerful tools,
namely dialysis and allograft kidney transplantation, to keep
patients alive. However, the long-term prognosis and qual-
ity of life of patients who depend on renal replacement
therapy (RRT) are poor, and healthcare expenses related to
RRT are rapidly increasing along with the number of pa-
tients with end-stage renal disease (ESRD) [2]. Therefore,
numerous studies have aimed to slow or stop the progres-
sion of CKD, including observational, prospective cohort
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studies of large numbers of participants to establish evi-
dence for intervention strategies [3–6]. Given that the
majority of these studies have been conducted in adult
CKD patients, it is uncertain whether the results of the
studies can be applied to pediatric patients [7]. First, the
etiology of pediatric CKD is different from that of adult
patients. Whereas diabetic nephropathy and hyperten-
sive nephropathy are major causes of CKD in adults,
congenital anomalies of kidney and urinary tract
(CAKUT) are the most common causes of CKD in chil-
dren. Children with CKD often suffer from impaired
growth and development in addition to common com-
plications of CKD, such as cardiovascular and metabolic
bone disease [8–15]. Furthermore, the life expectancy of
pediatric CKD patients is much longer than that of adult
CKD patients; therefore, pediatric patients require a
more aggressive approach to slowing the progression of
CKD and reducing its complications [16–20]. Fortunately,
excellent studies have investigated pediatric CKD, and
many issues concerning pediatric CKD are being resolved
[16, 21–24]. However, the majority of these studies are
from Western countries with small proportions of Asian
individuals.
We introduce a pediatric cohort study in Korea,
KNOW-Ped CKD (KoreaN cohort study for Outcome in
patients With Pediatric Chronic Kidney Disease), a na-
tionwide, ten-year prospective, observational cohort
study of pediatric CKD that was launched in 2011 as a
sub-cohort of KNOW-CKD, which was funded by the
Korean government [6]. The aim of the study is to an-
swer the following key questions and optimize the care
of patients with pediatric CKD: What are the common
etiologies of pediatric CKD in Korea? What factors affect
disease progression? What impact does pediatric CKD
have on patients’ and their families’ lives? Is the current
management for pediatric CKD ideal? Do medications,
socio-economic status, or other modifiable factors influ-
ence the course of pediatric CKD?
Methods/design
Seven major pediatric nephrology centers in Korea have
participated in the study and enroll 450 children with CKD
for comprehensive assessments of clinical findings, struc-
tured follow-up, and bio-specimen collection. To obtain
follow-up data from more than five years, the patients are
recruited during the first five years of this study. This study
was approved by the institutional review boards of the
participating centers, namely Seoul National University
Hospital, Asan Medical Center, Kyungpook National
University Hospital, Severance Hospital, Samsung Medical
Center, Jeju University Hospital, and Pusan National
University Children’s Hospital, and is included with the des-
ignation NCT02165878 at clinicaltrials.gov (submitted on
June 11, 2014). The annual reports summarizing the data of
this study will be available at our website (www.knowkid-
ney.org) upon completion of data collection.
Study population
Children <20 years of age with CKD are enrolled in this
study after informed consent is obtained from parents or
guardians. CKD is defined and staged according to the
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines as either kidney damage or glomerular filtra-
tion rate (GFR) <60 mL/min/1.73 m2 for ≥3 months
(Table 1) [25, 26]. GFR was estimated using the bedside
CKiD formula [27]. For those <2 years old, operational
staging of CKD was defined by the authors considering
age-appropriate normal values of estimated GFR (eGFR),
as shown in Table 1 [25, 28, 29].
The inclusion and exclusion criteria are presented in
Table 2. CKD stage I with potentially progressive renal
diseases or bilateral renal anomalies/defects is included,
and CKD stage V, which requires maintenance renal
replacement therapy, is excluded.
Data collection
After obtaining informed consent, the following clinical
information is collected: medical history, anthropometric
measurements, laboratory tests and imaging studies ac-
cording to the schedule presented in Table 3. The eti-
ology of CKD is determined from clinical findings,
classified according to the North American Pediatric
Renal Trials and Collaborative Studies (NAPRTCS) data-
base [21] after modification, and categorized into one of
the following three groups: CAKUT, glomerulonephro-
pathy, and other. For the analysis of CKD progression
rate, two time points are recorded along with eGFR on
those dates; the date on which the diagnosis of etiologic
kidney disease was made and the date when deterior-
ation of renal function (CKD stage 3) was observed. The
questionnaires of the Korea National Health and
Nutrition Examination Survey are completed by the par-
ticipants and their parents at the time of baseline assess-
ment as part of the medical history [30]. The parents’
heights and the age of maternal menarche are recorded
to assess the growth of the participants. Current medica-
tions included prescribed medications, over-the-counter
Table 1 CKD staging according to age (eGFR, mL/min/1.73 m2)
Stage/Age <2 weeks 2–7 weeks
(<2 months)
2–23 months
(<2 years)
≥2 years
1 ≥30 ≥49 ≥72 ≥90
2 20–29 33–48 48–71 60–89
3 10–19 16–32 24–47 30–59
4 5–9 8–15 12–23 15–29
5 <5 <8 <12 <15
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medications taken for more than one month, and alter-
native medications.
Serum creatinine, blood urea nitrogen, cystatin C,
parathyroid hormone, vitamin D, and urine chemistry
(creatinine, urea, electrolyte, protein and microalbumin)
are measured at a central laboratory (LabGenomics,
SeongNam-si, South Korea) within one day after sam-
pling to avoid inter-laboratory variation. At the central
laboratory, serum creatinine is measured using the isotope
dilution mass spectrometry (IDMS)-traceable method,
and cystatin C is determined using immunonephelometry.
Change in kidney volume is estimated by serial
ultrasonography as previously reported [31]. In a subset of
the participants, ambulatory blood pressure monitoring is
performed in addition to the casual office blood pressure
measurement. Isotopic GFR is measured in a subset of the
participants to compare the validity of equations to esti-
mate GFR in Korean children, including the bedside CKiD
equation, complete CKiD equation, and Flanders Metadata
equation [27, 32]. The patient’s quality of life is assessed
using Pediatric Quality of Life (PedsQoL), and behavioral
and neuropsychological statuses are evaluated using rele-
vant methods at regular intervals (Table 3) [33–40].
A DNA sample is collected at the time of enrollment
in the study. Serum and urine specimens are collected
annually and stored in a deep freezer for further studies.
Outcome variables
The primary endpoints of KNOW-Ped CKD are the pro-
gression of CKD, which is defined as a decline of eGFR
by ≥50 %; a requirement for renal replacement therapy;
and death. The secondary outcomes include the devel-
opment of left ventricular hypertrophy (left ventricular
mass/height^2.7 >95th percentile for age and sex),
Table 2 Inclusion and exclusion criteria
Inclusion Exclusion
Age, 0 to 19 years Unable or unwilling to provide
consent
CKD stages I to V according
to KDIGO guidelines
Renal replacement therapy
Informed consent Pregnant women
Current cancer
Table 3 Study measurements by visit
Parameter Screening Baseline 1 y 2 y 3 y 4 y 5 y 6 y 7 y 8 y 9 y 10 y
General Informed consent O
Demographic information O
Medical history O
KNHANES questionnaire O
Recent events O O O O O O O O O O
Medications O O O O O O O O O O O
Kidney CBC, blood/urine chemistry O O O O O O O O O O O
Kidney ultrasonographya O O O O O O O O O O O
Isotopic GFR (optional) O O O O
Growth Height, weight, waist/hip ratio, Tanner stage O O O O O O O O O O O
Bone age O O O O O O O O O O O
Cardio-vascular Blood pressure O O O O O O O O O O O
Electrocardiogram, chest X-ray O O O O O O
Echocardiography O O O
24-hour ambulatory blood pressure monitoring (optional) O O O O O O
Metabolic bone disease Parathyroid hormone, vitamin D O O O O O O
Bone mineral density O O O
Neuro-cognitive Pediatric quality of life O O O O O
IQ testb O O O O
Behavioral assessmentc O O O
Parental bonding instrumentd O O
Bio-repository Genetic sample O
Serum/urine sample O O O O O O O O O O O
aKidney ultrasonography is performed annually for patients with CAKUT and every 3 years for other patients
bKEDI-WISC (5–15 years) or K-WAIS (16 years or older) [33]. cChild Behavioral Checklist (CBCL) [34], ADHD Rating Scale-IV [35], State-Trait Anxiety Inventory (STAI)
[36], and Children’s Depression Inventory (CDI) [37]. dParental bonding instrument [38]
Kang et al. BMC Nephrology  (2016) 17:35 Page 3 of 7
hypertension (>95th percentile for age, sex and height),
impairment in growth (height Z score <−1.88 or weight
Z score <−1.65), deviation from the Korean average
ranges of neuropsychological and behavioral status,
stunted growth of renal volume, and quality of life as
well as changes from the baseline values.
Statistical methods and analysis plan
The continuous variables of characteristics are presented
using descriptive statistics with mean ± standard deviation
for continuous variables and number and proportion for
categorical variables. These variables will be compared
using a one-way analysis of variance or Kruskal-Wallis test
for the continuous variables and a chi-squared test or
Fisher’s exact test for the categorical variables as appropri-
ate. The time-to-event analysis will be the primary statis-
tical method for analyzing the relationship between
clinical characteristics and outcome variables, such as the
progression of CKD, development of left ventricular
hypertrophy, development of hypertension and impair-
ment of growth. To analyze the primary outcome, we will
apply the sub-distribution hazard models to our dataset
with the competing risk event (progression of CKD or
death without CKD) to evaluate the relative effects of co-
variates and cumulative incidence function [41].
Interim report of baseline characteristics
From July 2011 to December 2013, 322 patients
(218:104) were enrolled in the study. The average age at
the time of enrollment was 10.0 ± 5.4 years (yrs). The
etiologies of CKD included congenital renal dysplasia/
hereditary disease (49 %), reflux nephropathy/chronic
pyelonephritis (22 %), primary glomerular diseases
(16 %), secondary glomerular diseases (4 %), and others.
The stages of CKD were I for 15 %, II for 19 %, IIIa for
17 %, IIIb for 17 %, IV for 19 %, and V for 13 % of the
cases. The following proportions of participants accord-
ing to age group were noted: 10 % of patients were
<2 years, 16 % were 2 to 5 years, 28 % were 6 to 11 year,
and 47 % were 12 to 19 years. One-third of enrolled pa-
tients had histories of urinary tract infection, and 9 %
exhibited developmental delay. At baseline, hypertension
was noted in 27 % of patients, hyperlipidemia in 49 %,
anemia in 45 %, and iron deficiency in 25 %. Growth
delay was observed even in the early stage of CKD, with
mean height and weight Z scores of −0.88 and −0.91, re-
spectively, especially in younger (<6 years) patients with
advanced CKD (IV and V). The baseline characteristics
of the participants are summarized in Table 4.
Discussion
KNOW-Ped CKD is a prospective cohort study on Asian
pediatric CKD with long-term follow-up. Although sev-
eral investigations of school urinary screening and CKD
have been reported, comprehensive studies on CKD have
been rare in Asian countries [24, 42–49]. To the best of
our knowledge, only one prospective study has been per-
formed, involving 447 Japanese children with CKD
stages III-V with a relatively short follow-up period [43].
Therefore, primary renal disease and progression rates
in the earlier stages of CKD and their risk factors for
progression over an extended period have yet to be in-
vestigated in Asian children. The CKiD study, a leading,
comprehensive, prospective cohort study of pediatric
CKD, indicated that non-Caucasian race was a determin-
ant of proteinuria, which was subsequently a prognostic
factor for CKD progression, implying a difference in pro-
gression among races for pediatric CKD [22, 50]. Add-
itionally, outstanding pediatric CKD cohort studies,
namely the CKiD study and the 4C study, as well as the
Japanese national study, enrolled children with de-
creased eGFR, which excluded those with CKD stages I
and II. In KNOW-Ped CKD, Korean children with CKD
of stages I to V are enrolled.
Although advanced CKD tends to progress to ESRD,
many children remain at stage I or II for a long time.
The risk factors for progression in these patients remain
unknown. In some children, at least transiently, renal
function appears to recover. With the KNOW-Ped CKD
study, we will investigate the determinants of prognosis
for CKD stages I and II. Additionally, annual measure-
ments of the kidney size in this study will answer the fol-
lowing questions: 1) Does the kidney volume in CKD
correlate with renal function? 2) How much kidney
growth is necessary for functional improvement? With
KNOW-Ped CKD, we will be able to delineate the char-
acteristics of Asian pediatric CKD, which will lead to a
better understanding of the entire progression of CKD
in children. We will also identify the similarity and dif-
ferences among different ethnicities in pediatric CKD,
enabling us to customize therapeutic management.
Another characteristic of KNOW-Ped CKD is that this
study enrolls the majority of pediatric pre-dialysis CKD
patients in Korea. According to the data from Health
Insurance Review and Assessment Service of the Korean
National Health Insurance Program, a unique and
obligatory public healthcare program in Korea, CKD
patients <20 years of age numbered approximately 700 in
2014 [51]. Excluding the number of ESRD under renal re-
placement therapy, KNOW-Ped CKD is expected to enroll
more than half of the total Korean pediatric CKD patients
with the participation of seven major pediatric nephrology
centers. Therefore, this cohort study will reflect the
current status of pediatric CKD in Korea fairly accurately.
Staging of CKD in KNOW-Ped CKD is based on the bed-
side CKiD equation. Although this equation has not yet
been validated in Korean children, the bedside CKiD equa-
tion is simple and easy and therefore useful in clinical
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practice. Therefore, the authors expect that findings based
on this equation, after validation via the KNOW-Ped CKD
study, can be readily applied in patient care. Measuring
GFR using the clearance of injected isotopic material is per-
formed in a subset of the participants to investigate
whether known pediatric eGFR estimation equations are
applicable in Korean children. Regarding the staging of
CKD, categorizing CKD stages in older children cannot be
applied for children <2 years because the normal GFR is
lower in children <2 years of age [26]. Although the
KDIGO guidelines suggest classifying normal, moderate, or
severe reduction in GFR for children <2 years old, staging
of CKD reflecting kidney growth is necessary to assess the
progression of CKD. Therefore, we defined operational
GFR cut-offs as follows: stage I: eGFR ≥75 % of normal
GFR for age; stage II: eGFR 60 to 74 % of normal GFR for
age; stage IIIa: eGFR 45 to 59 % of normal GFR for age;
stage IIIb: eGFR 30 to 44 % of normal GFR for age; stage
IV: eGFR 15 to 29 % of normal GFR for age; and stage V:
eGFR <15 % of normal GFR for age [29, 52, 53]. This oper-
ational definition should be evaluated and possibly modified
throughout this study given that it has not been validated.
Additionally, when interpreting the results, it must be
considered that not all of the formulas for eGFR estimation
are generated by creatinine values measured using the same
method.
Three years after launching the KNOW-Ped CKD study,
more than 300 children with CKD have participated in
this study. Additional analysis will be conducted upon the
completion of enrollment; however, the distribution of the
etiology of CKD is similar to that of previous reports, in-
cluding CKiD and the Japanese nationwide survey study
[24, 54]. The CKD complications of hypertension, growth
retardation, anemia, and metabolic derangement were ob-
served as expected. These findings reveal that our current
management of pediatric CKD in Korea has room for im-
provement, such as early evaluation and intervention for
iron deficiency in this population.
Although this study has some limitations, such as the
use of the operational definition of CKD staging for youn-
ger patients and eGFR equations that have not yet been
verified in Korean children, we expect that KNOW-Ped
CKD, a prospective cohort study in pediatric CKD for a
long-term period in an Asian country, will reveal more
comprehensive characteristics of pediatric CKD, especially
in its earlier stage, and the risk factors of progression that
Table 4 Clinical characteristics of KNOW-Ped CKD
CKD Stage Total I II IIIa IIIb IV V
Patient Number 322 50 (15.5) 61 (18.9) 54 (16.8) 56 (17.4) 60 (18.6) 41 (12.7)
M:F (Male, %) 218:104 (67.7) 31:19 (62.0) 43:18 (70.5) 33:21 (61.1) 36:20 (64.3) 42:18 (70.0) 33:8 (80.5)
Age (years) 10.00 ± 5.45 7.04 ± 4.22 10.39 ± 5.61 11.50 ± 5.08 9.95 ± 5.36 9.48 ± 5.71 11.90 ± 5.42
Primary Kidney Disease
CAKUT 198 (61.49) 17 (34.00) 38 (62.3) 30 (55.56) 41 (73.21) 43 (71.67) 29 (70.73)
GN 93 (28.88) 31 (62.00) 16 (26.23) 15 (27.78) 12 (21.43) 10 (16.67) 9 (21.95)
Others 31 (9.63) 2 (4.00) 7 (11.48) 9 (16.67) 3 (5.36) 7 (11.67) 3 (7.32)
Age Group
<2 years 31 (9.63) 6 (12.00) 6 (9.83) 2 (3.70) 4 (7.14) 9 (15.00) 4 (9.76)
2–5 years 50 (15.53) 13 (26.00) 12 (19.67) 8 (14.81) 8 (14.29) 7 (11.67) 2 (4.88)
6–11 year 91 (28.26) 21 (42.00) 8 (13.11) 12 (22.22) 20 (35.71) 20 (33.33) 10 (24.39)
12–19 years 150 (46.58) 10 (20.00) 35 (57.373) 32 (59.26) 24 (42.856) 24 (40.00) 25 (60.98)
Growth, z score
Height −0.88 ± 1.43 −0.42 ± 1.09 −0.49 ± 1.41 −0.61 ± 1.32 −1.11 ± 1.22 −1.33 ± 1.62 −1.43 ± 1.58
Weight −0.91 ± 1.65 −0.24 ± 1.39 −0.56 ± 1.69 −0.67 ± 1.34 −1.01 ± 1.4 −1.68 ± 1.88 −1.34 ± 1.7
eGFR (mL/min/1.73 m2) 53.1 ± 40.22 127.39 ± 36.16 68.98 ± 10.21 52.28 ± 4.57 36.03 ± 4.7 20.87 ± 5.42 10.46 ± 3.02
Hemoglobin (g/dL) 12.1 ± 1.95 12.49 ± 1.21 13 ± 2.1 12.61 ± 1.94 12.34 ± 1.89 11.19 ± 1.6 10.65 ± 1.74
Transferrin saturation (%) 27 ± 16 29 ± 28 26 ± 13 27 ± 13 28 ± 13 25 ± 12 29 ± 12
Cholesterol (mg/dL) 183 ± 59 197 ± 86 175 ± 46 190 ± 50 179 ± 574 184 ± 504 171 ± 61
Intact PTH (pg/mL) 119 ± 178 40 ± 39 46 ± 22 66 ± 47 99 ± 857 193 ± 217 302 ± 327
25(OH)D3 (ng/mL) 20.86 ± 10.09 20.02 ± 8.75 20 ± 10.62 21 ± 9 22 ± 9 21 ± 11 19 ± 10
u Protein/Cr (mg/mg) 1.77 ± 5.95 3.76 ± 14.36 0.8 ± 2.09 1.17 ± 2.08 1.44 ± 2.29 1.9 ± 2.01 1.88 ± 1.52
LVMI (g/m2.7) 70 ± 22 71 ± 21 71 ± 23 65 ± 18 66 ± 17 70 ± 24 80 ± 26
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can be translated into better management of these pa-
tients through international collaboration with existing
cohort studies.
Ethics approval and consent to participate
This study was approved by the institutional review
boards of the participating centers, namely Seoul National
University Hospital, Asan Medical Center, Kyungpook
National University Hospital, Severance Hospital,
Samsung Medical Center, Jeju University Hospital,
and Pusan National University. Children <20 years of age
with CKD are enrolled in this study after informed con-
sent is obtained from parents or guardians.
Consent for publication
Not applicable.
Availability of data and material
All data is included within the article.
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